GeneCentric Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GeneCentric Therapeutics, Inc.
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
The North Carolina firm convinced investors to pledge $88 million and layered $50 million in federal small-business loans on top. It has quickly put the funds to work.
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
The 2013 life sciences IPO boom does not necessarily augur more of the same for those biotechs now lining up to go public. Plus financing news from Juno Therapeutics, GlycoMimetics, Ultragenyx and Alkermes.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- GeneCentric Diagnostics Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.